Berlin Cures BC 007 –
Clinical Development Status Update.

Berlin Cures is planning a phase II study at several clinical centers with the active substance BC 007 for the indication Long COVID. Once all the necessary approvals have been obtained, the first patients will be enrolled in this study. At that time, it will also be announced which clinical centers can be contacted. We ask all those affected to refrain from making enquiries directly to Berlin Cures, as our company is not allowed to intervene in the selection of study participants.

Please use a modern web browser